ATE210454T1 - Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins - Google Patents

Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins

Info

Publication number
ATE210454T1
ATE210454T1 AT96117245T AT96117245T ATE210454T1 AT E210454 T1 ATE210454 T1 AT E210454T1 AT 96117245 T AT96117245 T AT 96117245T AT 96117245 T AT96117245 T AT 96117245T AT E210454 T1 ATE210454 T1 AT E210454T1
Authority
AT
Austria
Prior art keywords
lfa
allotransplants
xenotransplants
administration
binding protein
Prior art date
Application number
AT96117245T
Other languages
English (en)
Inventor
Barbara Wallner
Christopher Benjamin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE210454T1 publication Critical patent/ATE210454T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96117245T 1991-10-07 1992-10-06 Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins ATE210454T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77270591A 1991-10-07 1991-10-07
US85070692A 1992-03-12 1992-03-12

Publications (1)

Publication Number Publication Date
ATE210454T1 true ATE210454T1 (de) 2001-12-15

Family

ID=27118640

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96117245T ATE210454T1 (de) 1991-10-07 1992-10-06 Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins

Country Status (9)

Country Link
EP (2) EP0786255B1 (de)
JP (2) JPH07502495A (de)
AT (1) ATE210454T1 (de)
AU (1) AU678141B2 (de)
CA (1) CA2120731C (de)
DE (1) DE69232295T2 (de)
DK (1) DK0786255T3 (de)
ES (1) ES2169783T3 (de)
WO (1) WO1993006852A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE161190T1 (de) * 1991-10-07 1998-01-15 Biogen Inc Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DK0749323T3 (da) * 1994-03-08 2001-02-05 Dana Farber Cancer Inst Inc Fremgangsmåder til modulering af T-celle-anergi
AU2006202939B2 (en) * 1994-03-08 2008-11-20 Dana-Farber Cancer Institute, Inc. Methods of modulating T cell unresponsiveness
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
WO2000012113A2 (en) * 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells using a cd2-binding agent, and compositions
EP1637155A1 (de) * 1998-08-31 2006-03-22 Biogen Idec MA Inc. Verfahren zur Modulierung von "Memory-Effector" T- Zellen unter Verwendung eines CD2-Bindungsagenses und Zusammensetzungen
AU2980900A (en) 1999-02-04 2000-08-25 General Hospital Corporation, The Methods for human allografting
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
WO2005115436A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
AU2019242451B2 (en) * 2018-03-29 2024-05-09 Pfizer Inc. LFA3 variants and compositions and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260880A3 (de) * 1986-09-11 1990-03-07 Dana-Farber Cancer Institute, Inc. Verfahren zur Auslösung der Zytotoxizität
EP0280578B1 (de) * 1987-02-26 1993-12-15 Dana-Farber Cancer Institute, Inc. Reinigung von LFA-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
JPH04506666A (ja) * 1990-01-24 1992-11-19 バイオジェン，インコーポレイテッド ワクチンアジュバントとしてのｌｆａ―３
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
ATE161190T1 (de) * 1991-10-07 1998-01-15 Biogen Inc Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung

Also Published As

Publication number Publication date
CA2120731A1 (en) 1993-04-15
WO1993006852A3 (en) 1993-07-22
AU2889192A (en) 1993-05-03
JP2003128579A (ja) 2003-05-08
EP0786255A1 (de) 1997-07-30
AU678141B2 (en) 1997-05-22
CA2120731C (en) 2008-08-19
JPH07502495A (ja) 1995-03-16
ES2169783T3 (es) 2002-07-16
DE69232295T2 (de) 2002-07-18
DK0786255T3 (da) 2002-04-15
WO1993006852A2 (en) 1993-04-15
DE69232295D1 (de) 2002-01-24
EP0607353A1 (de) 1994-07-27
EP0786255B1 (de) 2001-12-12

Similar Documents

Publication Publication Date Title
ATE210454T1 (de) Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins
DE69312077T2 (de) Behandlung von autoimmun- und entzundungskrankheiten
Spiegel et al. Prolactin and growth hormone release by morphine in the rat: different receptor mechanisms
DE69014137T2 (de) Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
DE69027121T2 (de) Bindeligande für tumornekrosisfaktor
US5055289A (en) Interferon antibody therapeutic compositions having an extended serum half-life
JPH0674208B2 (ja) ＧＨＬ−Ｃｕの創傷治癒および抗炎症剤としての使用
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
PT1107749E (pt) Derivados do acido fumarico para o tratamento da rejeicao de transplantes
SE8902638D0 (sv) Stabilized protein or peptide conjugates
ATE56365T1 (de) Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung.
PT621786E (pt) Inducao da tolerancia a xenoenxertos
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
EP0335133A3 (de) Arzneistoffabgabe mit Hilfe eines Lungentensids zur Absorptionsförderung
GR3024204T3 (en) Lymphocyte-associated cell surface protein
ATE44156T1 (de) Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie.
Witte et al. Membranous glomerulonephritis associated with chronic progressive demyelinating neuropathy
DE69122960T2 (de) Verfahren und zubereitungen für die behandlung von verletzungen
Umo Effect of prostaglandin F2α on the ultrastructure and function of sheep corpora lutea
Busch et al. Human renal allografts: Glomerular deposits of horse immunoglobulin G and nephritis following administration of antilymphocyte globulin
Jungeblut et al. Inactivation of poliomyelitis virus and of diphtheria toxin by various endocrine principles
MANCILLA-JIMENEZ et al. Antitubular basement membrane antibodies in renal allograft rejection
Doak et al. Use of antilymphocyte globulin after cadaveric renal transplantation
KOBAYASHI et al. HYPERACUTE REJECTION OF RENAL ALLOGRAFTS IN THE PRIMATE: PROTECTIVE EFFECT OF F (ab'): 2: FRAGMENT OF HYPERIMMUNE SERUM
Struck Immunological investigations of antigenicity and specificity of soluble collagen fractions: IV. Anaphylaxis and allergy experiments

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner